Business
Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain
Prof. Schroeder to advise on SCI-160 formulation development to enhance biological effect and extended effect duration TEL AVIV, Israel, March 30, 2022 (GLOBE
About this update from Scisparc Ltd.
[{"type":"text","content":"Prof. Schroeder to advise on SCI-160 formulation development to enhance biological effect and extended effect duration TEL AVIV, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the \"Company\" or \"SciSparc\"), today announced the appointment of Professor Avi Schroeder as a member of the Company's Scientific Advisory Board (SAB). As a member of the SAB, Prof. Schroeder will support the development of the Company's top-tier, proprietary, investigational drug candidate SCI-160 program for the treatment of pain. Prof. Schroeder will advise the Company on the formulation development of SCI-160 to enhance the proprietary synthetic CB2 receptor agonist’s biological effect and extend effect duration. The Company previously achieved positive results in a series of pre-clinical trials in which the efficacy and safety of SCI-160 was demonstrated in both acute and chronic pain. Prof. Schroeder is the head of the Targeted Drug Delivery and Personalized Medicine Group, at the Technion, Israel Institute of Technology and has translational experience with the development of liposome-based clinical systems. He is the author of scientific papers in the field of nanotechnology and medicine and is the inventor on 14 patents, and recipient of 20 national and international innovation awards. Prof. Schroeder is a scientific entrepreneur, starting five successful Technion spin-outs. Prof. Schroeder received three degrees in Chemical Engineering from the Ben-Gurion University of the Negev and his postdoctoral training took place at MIT. Dr. Adi Zuloff-Shani, SciSparc's Chief Technologies Officer, commented, \"As we continue to make progress in our innovative program to treat pain, utilizing our non-opioid analgesic pain management solution, SCI-160, reinforcing our SAB is essential. Our plans are to commence the Pre-IND process further this year, followed by an FDA Investigational New Drug (IND) Phase I study application for our treatment for pain. We welcome Prof. Schroeder and the great contribution he will bring to our SAB, that already includes a diverse list of renowned researchers, physicians and experts advising the company.\" The Company’s top-tier, investigational drug candidate S...